Objectives: Impulse control disorders (ICDs) are common among patients with Parkinson's disease (PD). Risk factors identified for developing ICDs include young age, family history, and impulsive personality traits. However, the association of these potentially disabling disorders with nondopaminergic drugs and sleep disorders has been understudied. Our objective was to examine the association between ICDs and nondopaminergic medications and sleep disorders. 
| INTRODUCTION
Impulse control disorders (ICDs) are repetitive and reward-based behaviors commonly observed in patients with Parkinson's disease (PD) (Weintraub et al., 2010) . ICDs refer to four major disorders including pathological gambling, hypersexuality, compulsive shopping, and binge eating (Voon & Fox, 2007) . Other related impulse control behaviors are classified separately and include punding, hobbyism, hoarding, and dopamine dysregulation syndrome (DDS). Epidemiological studies report an estimated prevalence of 8.1%-35% in patients with PD, and around 14% will report having at least one active ICD (Maloney, Djamshidian, & O'Sullivan, 2017) . The underlying etiology for an increased prevalence of ICDs in patients with PD is not fully known. ICDs are commonly attributed to hyperdopaminergic states, resulting primarily from levodopa (LD) and dopamine agonists (DAs) (Ray & Strafella, 2010) .
These drugs play a large role in reward-motivated behaviors, and their contribution to the risk of developing ICDs is reported to be at least 2-3.5 times higher with DAs than with levodopa (Weintraub et al., 2010) . Other reported risk factors associated with ICDs include young age, smoking, alcohol use, family history of pathological gambling, and having impulsive personality traits (Sharma et al., 2015) . Several studies have explored the possible relationship and underlying mechanisms between impulsivity and sleep disorders in patients with PD (Djamshidian, Poewe, & Hogl, 2015; Scullin et al., 2013 ).
However, these have shown no association between polysomnography (PSG)-confirmed REM behavioral sleep disorder (RBD) and ICDs (Bayard et al., 2014; Romenets et al., 2012) . The role of other PSGconfirmed sleep disorders in ICDs has not been studied. Furthermore, the role of commonly used nondopaminergic drugs in ICDs has also not been investigated. Identifying additional risk factors associated with ICDs is critical to better understand the pathophysiology of these disorders that may lead to prevention or early management of ICDs.
These patients experience significantly lower disability and healthrelated quality of life, greater functional impairment, and increased caregiver burden (Maloney et al., 2017) . In this study, we aimed to determine the association between ICDs and nondopaminergic drugs and with the presence or absence of sleep disorders.
| METHODS
This is a retrospective study of 53 patients with PD from the National (Hughes, Daniel, Kilford, & Lees, 1992) . Patients were included if they performed a complete PSG screening analysis within 1 year of sleep complaints. We documented demographics, disease duration, family history of PD, clinical variables, levodopa equivalent dosage (LED), and dopaminergic medications, including LD, DAs, and monoamine oxidase type B inhibitors (MAOBIs). We calculated LED using the following formula: regular LD dose + LD controlled release dose × 0.75 + LD × 0.33 if entacapone + pramipexole dose × 100 + ropinirole dose × 20 + rotigotine dose × 30 + pergolide dose × 1 + bromocriptone dose × 10 + selegiline dose × 10 + rasagiline dose × 100 + amantadine dose × 1 (Tomlinson et al., 2010) .
We also documented the presence or absence of nondopaminergic drugs including antidepressants, sleep inductors, and antipsychotics. Clinical variables were measured using the Unified Parkinson Disease Rating Scale (UPDRS) in the "on" medication state and the Hoehn and Yahr (H&Y) scale, both scored by a movement disorderstrained neurologist. The Questionnaire for Impulse Control Disorders in Parkinson's Disease Rating Scale (QUIP-RS) was used to screen for ICDs. This scale is validated as screening measure that accurately diagnoses ICDs in PD through a self-guided questionnaire.
The QUIP-RS consists of an ICD subscore A-D including the four main ICDs (A-pathological gambling, B-hypersexuality, C-compulsive shopping, and D-binge eating) and a total QUIP-RS score including A-D subscore plus scores from sections E (hobbyism) and F (punding). The questionnaire also evaluates medication usage; however, it is not included in the total score. Higher scores indicate a higher frequency of behaviors ). All subjects com- 
| Statistical analysis
To investigate the relationship between ICDs, PSG-confirmed sleep disorders, and nondopaminergic drugs, we developed linear regression models. Dependent variables were either specific QUIP-RS items, subscores, or QUIP-RS total score. When appropriate and unless otherwise specified throughout, potential confounding variables were added to all models as independent variables. These included H&Y stage, age, gender, family history, disease duration, and UPDRS Part I, II, III, and IV scores. We used posthoc backward elimination to remove uninformative independent variables. We first analyzed the association between ICDs and scores for OSA, PLMD, and RBD as independent measures.
We developed separate models with dependent variables being individual scores from QUIP-RS as well as section subscores and total scores.
To extend these results, the next models we tested included medications as additional independent variables. Importantly, we included both dopaminergic and nondopaminergic drugs as predictor variables to examine the understudied relationship between nondopaminergic drugs and ICDs. Backward elimination was applied to drop uninformative predictors. All analyses were completed using R version 3.2 for Mac.
| RESULTS
Patient demographics and clinical characteristics, ICDs, and sleep variables are shown in Table 1 . Thirty-two (60.4%) patients were female.
The mean age was 61.6 years (SD = 10.9, range 31-81), and the mean disease duration was 6.6 years (SD = 6.8, range 1-43 years). UPDRS "on" medication state scores were as follows: part I of 13.9 (SD = 6.0), part II of 14.3 (SD = 8.5), part III of 27.7 (SD = 14.9), and part IV of 2.4 (SD = 3.4). The cohort had a H&Y stage of 2.2 (SD = 0.7), with 75.5% classified as stage I-II, 18.9% as stage III, and 5.7% as IV-V. Family history of tremors or PD was reported in 81.1% of the cohort. Nearly, all patients (98.1%) were receiving a dopaminergic drug with 75.5% receiving levodopa, 83.0% receiving DA, and 17% receiving MAOBIs.
The LED in our sample was 643.6 mg (SD = 432.5, range from 0 to 1927.5 mg). In regard to the presence or absence of nondopaminergic medications, 32.1% were on antidepressants, 15.1% on sleep inductors, and 1.9% on antipsychotics. ICDs were reported in ten patients (18.9%), with five patients (9.4%) having a combination of multiple ICDs. Binge eating was documented in four patients, abnormal sexual behaviors in four patients, pathological shopping in four, and pathological gambling in two patients. Hobbyism-punding was reported in eight patients. PSG results confirmed the diagnosis of sleep disorders in 43 patients (81.1%), where 30 patients (56.6%) were diagnosed with OSA, 26 patients (49.1%) with RBD, and 14 patients (26.4%) with PLMD. Twenty-two patients (41.5%) were diagnosed as having more than one sleep disorder. 
| QUIP-RS and sleep disorders

| QUIP-RS and nondopaminergic drugs
We found that QUIP-RS A-D subscore depended on the presence of DAs (β = 7.7, p = . Individual items from the QUIP-RS eating section were related to dopaminergic and nondopaminergic drugs. The eating total sub- Table 2 .
| DISCUSSION
In the present study, we investigated the association between ICDs Similarly, no data have been reported in regard to the relationship between sleep inductors and ICDs. Sleep inductors regulate sleep cycles through sedative interactions with GABA receptors located in the cerebral cortex, thalamus, and hypothalamus (Szabadi, 2006) . A recent study reported evidence that GABAergic dysregulation is correlated with impulsivity, supporting claims of previous studies that suggest an association between increased impulsivity and GABA modulating drugs, such as benzodiazepines (Hayes et al., 2014; Mick et al., 2017) .
We also observed a specific association of dopaminergics, antidepressants, and MAOBIs with QUIP-RS items related with eating behaviors.
Other factors not included in the analysis need to be considered before determining this association, such as genetic, environmental, and psychological factors (Saez-Francas et al., 2016) . Furthermore, given that data in this retrospective analysis lack indication of drug use, it is difficult to draw conclusions on the directionality of the association.
For that reason, precaution should be taken before making any casual conclusions in the data. There is scarce information on the interactions of nondopaminergic drugs on impulsivity pathways, and the small cohorts of patients that have been previously analyzed limit the applicability of the findings.
Our study did not support a significant association between ICDs and PSG-confirmed sleep disorder, which contrasts some of the previous studies reporting positive associations between RBD and ICD.
We can argue that these studies documented RBD through questionnaires which can provide subjective results (Bellosta Diago, Lopez Del
Val, Santos Lasaosa, López Garcia, & Viloria, 2016; Fantini et al., 2015; Kim et al., 2014) . In a cross-sectional study of 944 patients, ICDs were found to be more frequent in PD patients with RBD, especially punding; however, after controlling for age and disease duration, the positive results were no longer significant (Fantini et al., 2015) . Likewise, a cross-sectional study of 216 patients with PD using QUIP-RS as a measure to diagnose ICDs also found an association between ICDs and RBD (Kim et al., 2014) . Similar to our findings, studies in which RBD was confirmed through a PSG analysis have shown no significant associations between studied variables. Two previous studies have reported no association between ICDS and PSG-confirmed RBD (Bayard et al., 2014; Romenets et al., 2012) . Although no association was found between QUIP-RS scores and sleep disorders, significant associations were observed between QUIP-RS Item 1A scores (gambling) and the previous studies that used more subjective data on sleep disorderssuch as questionnaires-found an association with ICDs, studies that used a PSG to identify the presence of sleep disorders found no association with ICDs (Bayard et al., 2014; Bellosta Diago et al., 2016; Fantini et al., 2015; Kim et al., 2014; Romenets et al., 2012) . This discrepancy is probably due to the different screening tools that were utilized by the studies. Using PSGs to detect sleep disorders might provide more accurate data on sleep and enhance the objectivity of the analysis.
Several limitations of the present study should be considered before interpreting results. Our small sample size might not be representative of the PD population. For instance, the age range and disease duration ranges were relatively large. Furthermore, not all sleep disorders and nondopaminergic drugs were studied, nor the clinical indication for taking these drugs or the class of antidepressant, sleep inductors, or antipsychotic used. Future studies with more specific sample characteristics will be necessary to solidify the results presented here. It is also important to mention that the association between nondopaminergic drugs and ICDs could be bidirectional, which cannot be determined by our study that solely focused on drug use irrespective of indications. Our observation might have clinically relevant implications, and judicious use of nondopaminergic medications in
ICDs should be considered. It is also important to note that the R 2 values of the models were generally low, pointing to the multifaceted and complex relationship between ICDs and other factors in patients with PD. Future prospective, controlled studies may overcome some of our limitations. Namely, given the numerous nondopaminergic medications used in the PD population, larger sample sizes are necessary to isolate medications with the highest impact on impulsivity. Additionally, it should be noted that PD patients with ICDs underreport their impulsive natures (Weintraub, 2009 ). We caution that accurate diagnosis of
ICDs is a well-recognized difficulty that has yet to be easily overcome.
| CONCLUSIONS
Our results suggest that nondopaminergics may be risk factors for de- 
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